Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Vasoconstrictor Agents" patented technology

Drugs used to cause constriction of the blood vessels.

Compositions and methods for diagnosis and treatment of microvascular dysfunction and related diseases

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.
Owner:TEXAS A&M UNIVERSITY

Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues

PendingUS20260199127A1Tongue rootAnatomy
A heat exchanger is disclosed for causing cryolysis of adipose tissue of a human tongue. The heat exchanger includes a body having cooling channels for circulating fluids therein. The body forms a contact surface that contacts a portion of the dorsal surface of the tongue and a portion of the base of the tongue. The heat exchanger includes a pair of side walls extending from the body and forming a pair of side contact surfaces that are dimensioned so that they contact the dorsal and lateral surfaces of the tongue in a manner so as to constrict the tongue when the contact surface is in contact with the tongue. A method of treatment for apnea using the heat exchanger and / or administering a chemical adipolysis formulation / vasoconstriction agent is also disclosed.
Owner:CRYOSA INC

Doxycycline injection for sclerotherapy of lower eyelid festoons and malar edema

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.
Owner:LKF21 LLC

Methods and devices for treating targeted vasculature

PCT designated stageWO2025175279A1Peptide/protein ingredientsNanomedicineVasoconstrictor AgentsParent artery
A method of treating a hemorrhage with a treatment fluid includes delivering the treatment fluid to targeted vasculature including the hemorrhage to modulate blood flow to the targeted vasculature. The treatment fluid includes a viscosifying polymer, a hemostatic agent, a vasoconstrictor, or a combination thereof. A flow guide device including a cylindrical structure with a low porosity wall, wherein the flow guide device is configured to be deployed in a parent artery including ostia of targeted vasculature. The flow guide device can facility the delivery of a treatment fluid to targeted vasculature.
Owner:GLIA MEDICAL INC +1

Mutual Prodrugs of Cromoglicic Acid

Disclosed herein are mutual prodrugs of cromoglicic acid and topical antiseptics, antibiotics, anti-inflammatory agents, keratin softeners, vasoconstrictors, retinoids and retinoid-like drugs and their compositions thereof, and methods for, e.g., treating disorders, and conditions by administration of the compositions. Topical and oral compositions of mutual prodrugs of cromoglicic acid, and derivatives and analogs of cromoglicic acid are also provided.
Owner:SAMDOLITE PHARMACEUTICALS LLC